Disitamab vedotin - CAS 2136633-23-1

Disitamab vedotin (RC-48) is a newly developed antibody-active molecule conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), consisting of hertuzumab coupled to monomethyl auristatin E (MMAE) via a cleavable linker. Disitamab vedotin showed anti-tumor and anti-proliferative activities in gastric cancer cells with different HER-2 expression levels and inhibited the expression of HER-2 protein in gastric cancer cells.

EGFR, Antibody-Drug Conjugates (ADCs)

Tyrosine Kinase/Adaptors, Angiogenesis, Antibody-drug Conjugate/ADC Related, JAK/STAT signaling

2136609

0.98

-20°C

Ice Packs

Inhibitory Antibodies